- Home
- ROOT vs FOLD Comparison
ROOT vs FOLD Comparison
Compare ROOT & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROOT
- FOLD
- Stock Information
- Founded
- ROOT 2015
- FOLD 2002
- Country
- ROOT United States
- FOLD United States
- Employees
- ROOT N/A
- FOLD N/A
- Industry
- ROOT Property-Casualty Insurers
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- ROOT Finance
- FOLD Health Care
- Exchange
- ROOT Nasdaq
- FOLD Nasdaq
- Market Cap
- ROOT 2.3B
- FOLD 2.5B
- IPO Year
- ROOT 2020
- FOLD 2007
- Fundamental
- Price
- ROOT $95.81
- FOLD $8.11
- Analyst Decision
- ROOT Buy
- FOLD Buy
- Analyst Count
- ROOT 6
- FOLD 9
- Target Price
- ROOT $130.60
- FOLD $28.00
- AVG Volume (30 Days)
- ROOT 438.0K
- FOLD 3.5M
- Earning Date
- ROOT 10-29-2025
- FOLD 11-05-2025
- Dividend Yield
- ROOT N/A
- FOLD N/A
- EPS Growth
- ROOT N/A
- FOLD N/A
- EPS
- ROOT 4.73
- FOLD N/A
- Revenue
- ROOT $1,364,700,000.00
- FOLD $571,160,000.00
- Revenue This Year
- ROOT $27.41
- FOLD $20.98
- Revenue Next Year
- ROOT $9.74
- FOLD $20.74
- P/E Ratio
- ROOT $20.90
- FOLD N/A
- Revenue Growth
- ROOT 59.76
- FOLD 25.35
- 52 Week Low
- ROOT $36.87
- FOLD $5.51
- 52 Week High
- ROOT $181.14
- FOLD $12.65
- Technical
- Relative Strength Index (RSI)
- ROOT 47.82
- FOLD 65.66
- Support Level
- ROOT $94.78
- FOLD $7.61
- Resistance Level
- ROOT $102.47
- FOLD $8.29
- Average True Range (ATR)
- ROOT 4.57
- FOLD 0.27
- MACD
- ROOT 1.65
- FOLD -0.03
- Stochastic Oscillator
- ROOT 57.16
- FOLD 69.86
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.